Small Cell Lung Cancer Pipeline Outlook Report 2025: Leading Pharma Announces Historic Progress in Treatment Development | DelveInsight

DelveInsight's, "Small Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Small Cell Lung Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Small Cell Lung Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

* On 31 October 2025, Merck Sharp & Dohme LLC conducted a study will consist of two parts. Part 1 will assess the safety, tolerability, and efficacy of gocatamig and I-DXd at doses determined in study MK-6070-001 (NCT: NCT04471727). Part 2 will assess the safety and tolerability of gocatamig in participants in Japan and China. Part 3 will assess the safety, tolerability, and efficacy of gocatamig with durvalumab
* On 29 October 2025, Hoffmann-La Roche announced a study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
* On 27 October 2025, Daiichi Sankyo conducted a study is to assess whether treatment with I-DXd improves objective response rate (ORR) and prolongs overall survival (OS) compared with treatment of physician's choice among participants with relapsed SCLC.
* On 23 October 2025, Mirati Therapeutics Inc. conducted a phase 2 study of adagrasib monotherapy in which patients are randomized between two dosing regimens. The study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID without regard to food versus 400 mg BID with food) in patients with NSCLC with KRAS G12C mutation and who have received prior treatment with a platinum-based regimen and immune checkpoint inhibitor therapy.
* On 23 October 2025, Amgen initiated a study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
* On 22 October 2025, AstraZeneca announced a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
* On 22 October 2025, IDEAYA Biosciences organized a Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
* DelveInsight's Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
* The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
* Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.

Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non-small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa.

Small Cell Lung Cancer Emerging Drugs Profile

* AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

* APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

The Small Cell Lung Cancer Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
* Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.

Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline. Explore DelveInsight's expert-driven report today! @ Small Cell Lung Cancer Unmet Needs [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Small Cell Lung Cancer Companies

Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Small Cell Lung Cancer Developments @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
* Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.
* Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Small Cell Lung Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Small Cell Lung Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Small Cell Lung Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Pembrolizumab: Merck & Co
* Mid Stage Products (Phase II)
* Dostarlimab: GlaxoSmithKline
* Early Stage Products (Phase I)
* AMG 757: Amgen
* Preclinical/Discovery Stage Products
* S 055746: Vernalis
* Inactive Products
* Small Cell Lung Cancer Key Companies
* Small Cell Lung Cancer Key Products
* Small Cell Lung Cancer- Unmet Needs
* Small Cell Lung Cancer- Market Drivers and Barriers
* Small Cell Lung Cancer- Future Perspectives and Conclusion
* Small Cell Lung Cancer Analyst Views
* Small Cell Lung Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=small-cell-lung-cancer-pipeline-outlook-report-2025-leading-pharma-announces-historic-progress-in-treatment-development-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.